NCCN and Pfizer Announce New Biosimilars Research Projects in Oncology

The National Comprehensive Cancer Network® (NCCN) Oncology Research Program (ORP) in collaboration with Pfizer announced this week a list of ten selected organizations and their research projects that have been chosen to receive funding to study the safe, effective, and efficient adoption of biosimilars in oncology:

  1. American Society of Clinical Oncology, Inc., ASCO’s PracticeNET Learning Network (Analysis of Biosimilar Utilization and Perspectives within ASCO’s PracticeNET Learning Network)
  2. Baptist Memorial Hospital Tipton (Adoption of Biosimilars in Oncology)
  3. Cancer Support Community (Frankly Speaking About Cancer: Biosimilars – Researching Oncology Patient and Caregiver Perceptions)
  4. Cedars-Sinai Medical Center (Optimize Systemic Platform to Assure Quality, Value and Evidence-Based Decision Making on Biosimilar Products Use in Oncology Patients)
  5. City of Hope Medical Foundation (Challenges to Biosimilar Adoption in Community Oncology Due to Diverse Payer Preferences for Different Biosimilar)
  6. Houston Methodist (Impact of Discordant Preferred Drug Status between Hospitals and Payers for Chemotherapeutic Biosimilars)
  7. Roswell Park Comprehensive Cancer Center (Identifying Best Practices in Biosimilar Implementation)
  8. University of Illinois at Chicago (Developing a Human-Centered Information Packet to Increase Trastuzumab Biosimilars Uptake)
  9. The University of Texas at Austin (Biosimilar Optimization in Community Oncology Practice)
  10. UT Southwestern Medical Center (Developing a Clinical Decision Support Tool for Biosimilar Use in Oncology)

According to Wui-Jin Koh, MD, Chief Medical Officer of NCCN, “[t]hese projects will help us to determine best practices for using biosimilars—when safe and appropriate—and how to educate providers and patients about them.”